Targeting mast cells

Expert Opinion on Investigational Drugs

Volumn 13, Issue 7, 2004, Pages 739-741

  Norris, Alan ^a  

^a Almirall Prodesfarma SA ^*  (Spain)

Author keywords

tryptase; Cromoglycate; Mast cells; Mast cell stabiliser; Prostagandin D2; Tyrosine kinase Syk

Indexed keywords

ANDOLAST; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; ARACHIDONIC ACID; CROMOGLYCATE DISODIUM; CYTOKINE; HISTAMINE; HISTAMINE H4 RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; MONTELUKAST; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROTEIN KINASE INHIBITOR; PROTEIN KINASE SYK; PROTEINASE; R 112; S 5751; TRYPTASE INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; CELL ACTIVATION; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; EDITORIAL; ENZYME RELEASE; HISTAMINE RELEASE; HUMAN; INHALER; MAST CELL; QUANTITATIVE ANALYSIS; TARGET CELL;

ANIMALS; HUMANS; MAST CELLS;

EID: 3543068802     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.7.739     Document Type: Editorial

References (13)

1. PAWANKAR R, YAMAGISHI S, TAKIZAWA R et al.: Mast cell-IgE-and mast cell-structural cell interactions in allergic airway disease. Curr. Drug Targets Inflamn. Allergy (2003) 2(4):303-312.
2. MARSHALL JS, McCURDY JD, OLYNYCH T: Toll-like receptor-mediated activation of mast cells: implications for allergic disease? Int. Arch. Allergy Immunol. (2003) 132(2):87-97.
3. NORRIS AA, HOLGATE ST: Cromolyn sodium and nedocromil sodium. In: Allergy: Principles and Practice (5th Edition). ER Middleton et al. (Eds), Mosby-Year Book, MO, USA (1998):661-667
4. PERSIANI S, DAMATO M, MAKOVEC F et al.: Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. Biopharm. Drug. Dispos. (2001) 22(2):73-81.
5. GUYER B, SHIMAMOTO S, BRADHURST A et al.: The effect of novel inhibitor of mast cell activation on mediators, symptoms and nasal patency in allergic rhinitis. J. All. Clin. Immunol. (2004) 113(2):S28.
6. HE S, ASLAM A, GACA MD et al.: Inhibitors of tryptase as mast cell-stabilizing agents in the human airways: effects of tryptase and other agonists of proteinase-activated receptor 2 on histamine release. J. Pharmacol. Exp. Ther. (2004) 309(1):119-126.
7. KRISHNA MT, CHAUHAN A, LITTLE L et al.: Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J. Allergy Clin. Immunol. (2001) 107:1039-1045.
8. ERIN EM, ZACHARASIEWICZ AS, HIGGINS LA et al.: A reversible inhibitor of mast cell β-tryptase and trypsin (RWJ-58643) causes inhibition of symptoms, eosinophils and IL-5 following nasal challenge with timothy grass pollen in patients with allergic rhinitis. Am. J. Resp. Crit. Care Med. (2004) 169:A859.
9. HIRAI H, TANAKA K, YOSHIE O et al.: Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils and basophils via seventransmembrant receptor CRTH2. J. Exp. Med. (2001) 193:255-261.
10. ARIMURA A, YASUI K, KISHINO J et al.: Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J. Pharmacol. Exp. Ther. (2001) 298(2):411-419.
11. 4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br. J. Pharmacol. (2004) 142(1):161-171.
12. 4 receptor antagonist with anti-inflammatory properties. J. Pharmacol. Exp. Ther. (2004) 309(1 ):404-413.
13. MELLOR EA, FRANK N, SOLER D et al.: Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R. Proc. Natl. Acad. Sci. USA (2003) 100(20):11589-11593.